Non-muscle-invasive bladder cancer: An overview of potential new treatment options
Por:
Shore, ND, Redorta, JP, Robert, G, Hutson, TE, Cesari, R, Hariharan, S, Faba, G, Briganti, A, Steinberg, GD
Publicada:
1 oct 2021
Ahead of Print:
1 sep 2021
Resumen:
Aim: This review article summarizes the current clinical practice guidelines around disease definitions and risk stratifications, and the treatment of non-muscle-invasive bladder cancer (NMIBC). Recently completed and ongoing clinical trials of novel and investigational therapies in Bacillus Calmette-Guerin (BCG)-naive, BCG-recurrent, and BCG-unresponsive patient populations are also described, e.g., those involving immune checkpoint inhibitors, targeted therapies, other chemotherapy regimens, vaccines, and viral-or bacterial-based treatments. Finally, a brief overview of enhanced cystoscopy and drug delivery systems for the diagnosis and treatment of NMIBC is provided.
Background: A global shortage of access to BCG is affecting the management of BCG-naive and BCG-recurrent/unresponsive NMIBC; hence, there is an urgent need to assist patients and urologists to enhance the treatment of this disease.
Methods: Searches of ClinicalTrials.gov, PubMed, and Google Scholar were conducted. Published guidance and conference proceedings from major congresses were reviewed.
Conclusion: Treatment strategies for NMIBC are generally consistent across guidelines. Several novel therapies have demonstrated promising antitumor activity in clinical trials, including in high-risk or BCG-unresponsive disease. The detection, diagnosis, surveillance, and treatment of NMIBC have also been improved through enhanced disease detection. (C) 2021 Pfizer Inc. and the Author(s). Elsevier Inc.
Filiaciones:
Shore, ND:
Carolina Urol Res Ctr, Myrtle Beach, SC USA
Redorta, JP:
Univ Autonoma Barcelona, Dept Urol, Fdn Puigvert, Barcelona, Spain
Robert, G:
Univ Bordeaux, CHU Bordeaux, Dept Urol, Bordeaux, France
Hutson, TE:
Baylor Charles A Sammons Canc Ctr, Texas Oncol, Dallas, TX USA
Cesari, R:
Pfizer Oncol, Milan, Italy
Hariharan, S:
Pfizer Oncol, New York, NY USA
Faba, G:
Univ Autonoma Barcelona, Dept Urol, Fdn Puigvert, Barcelona, Spain
Briganti, A:
Univ Vita Salute San Raffaele, Dept Urol, Milan, Italy
Steinberg, GD:
NYU, NYU Langone Hlth, NYU Urol Associates,Goldstein Bladder Canc Progra, Perlmutter Canc Ctr,NCI Designated Comprehens Can, New York, NY 11201 USA
hybrid
|